Vidaza (correction)
Executive Summary
Pharmion licensed full development and commercialization rights for Vidaza (azacitidine) from Pharmacia in 2001 (1"The Pink Sheet" Sept. 1, 2003, p. 24). A March 7 2story on MGI's Dacogen, inaccurately said Pharmion copromotes Vidaza with Pfizer. Vidaza, which cleared FDA in May 2004, is the only product approved for treatment of MDS...
You may also be interested in...
MGI Dacogen Dosing Strategy Will Consider Reimbursement, Convenience
MGI Pharma is evaluating more convenient dosing strategies for its oncologic Dacogen in patients with myelodysplastic syndromes
Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder
Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.